ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2254

The Urge for Mobile Apps in Rheumatology – a German Patient Perspective

Johannes Knitza1, Christina Raab 1, Antonia Lambrecht 1, David Simon 2, Melanie Hagen 1, Sara Bayat 1, Georg Schett 3, Arnd Kleyer 1 and Axel Hueber 4, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; Sektion Rheumatologie, Sozialstiftung Bamberg, Klinikum Bamberg, Bamberg, Germany, Erlangen, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Clinical research methods, MHealth, patient preferences, social media and website

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Mobile health applications have the potential of saving costs, empowering patients and improving treatment outcomes. Furthermore, the use of medical apps in routine care is increasing among rheumatologists[1]. In order to turn digitalization and all its benefits into practice it is crucial to include the main stakeholders. We therefore wanted to explore the needs and attitudes of patients with rheumatic diseases concerning mobile apps.

Methods: Between December 2018 and January 2019, 224 consecutive patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis were seen at one rheumatology outpatients clinic and asked to complete a paper-based survey. This survey evaluated the individual mobile app experiences, preferences and attitudes. This study was approved by the Ethics committee (No. 418-18B) and all patients consented to the study.

Results: Patient demographics are displayed in Table 1. 198 patients (90%) regularly used a smartphone, 103 patients (46%) regularly used social media. 144 (65%) patients believed that using medical apps could be beneficial for their health. Only 9 patients (4%) were currently using medical apps and only 24 patients (11%) stated that they knew useful rheumatology websites / mobile apps. 211 patients (96%) would agree to share their mobile app data for research purposes if data was transferred by a secure and anonymized / pseudonymized method. 166 patients (76%) would welcome official mobile app recommendations from the national rheumatology society. Only 33% would not consent to future data entry (Figure 1), whereas average time for entry should not exceed more than 5 minutes.  The most popular three app features desired were information about the disease, medication and sports and nutrition (Figure 2).

Conclusion: Most patients possessed smartphones and believed that using medical apps could be beneficial for their health. They were also willing to share data for research purposes. However only a small minority were currently using medical apps or knew useful apps. Patients stated that they would welcome app recommendations and information provided by apps. We could successfully identify unmet needs and patient priorities to accelerate and guide the way of mobile apps into routine rheumatology care.

References: 1. Knitza, J. et al. [Use of medical apps and online platforms among German rheumatologists : Results of the 2016 and 2018 DGRh conference surveys and research conducted by rheumadocs].Z Rheumatol, 2018.


Disclosure: J. Knitza, None; C. Raab, None; A. Lambrecht, None; D. Simon, None; M. Hagen, None; S. Bayat, None; G. Schett, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, 8, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB, 5, BMS, Celgene, GSK, Lilly, Novartis, 2; A. Kleyer, None; A. Hueber, None.

To cite this abstract in AMA style:

Knitza J, Raab C, Lambrecht A, Simon D, Hagen M, Bayat S, Schett G, Kleyer A, Hueber A. The Urge for Mobile Apps in Rheumatology – a German Patient Perspective [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-urge-for-mobile-apps-in-rheumatology-a-german-patient-perspective/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-urge-for-mobile-apps-in-rheumatology-a-german-patient-perspective/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology